You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Phase III, NSCLC, Almonertinib, uncommon EGFR mutation, first-line therapy，platinum-based chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Guangzhou (Almonertinib, chemo)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun yat-sen Univerisity Cancer Center
Jun 30, 2021

NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • HS-10241+ Almonertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • (no location specified)
Oct 29, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 17, 2023

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))

Withdrawn
  • NSCLC Stage IV
  • combination regimen tremelimumab /durvalumab
  • platinum-based chemotherapy (SoC)
  • Gauting, Germany
    Asklepios Fachkliniken München-Gauting
Sep 26, 2022

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

Non Small Cell Lung Carcinoma NSCLC Trial in Worldwide (Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine +

Active, not recruiting
  • Non Small Cell Lung Carcinoma NSCLC
  • Durvalumab (MEDI4736)
  • +5 more
  • Anaheim, California
  • +92 more
Jan 31, 2023

Advanced/Metastatic NSCLC (NSCLC) Trial in China (YK-209A tablet, Pemetrexed+carboplatin/Cisplatin)

Not yet recruiting
  • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • Bengbu, Anhui, China
  • +51 more
Mar 11, 2023

Non Small Cell Lung Carcinoma NSCLC Trial in Worldwide (Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine +

Active, not recruiting
Has Results
  • Non Small Cell Lung Carcinoma NSCLC
  • Durvalumab +Tremelimumab
  • +5 more
  • Anaheim, California
  • +210 more
Jan 4, 2023

Squamous NSCLC Trial in Shanghai (Sintilimab, Gemcitabine, Cisplatin)

Active, not recruiting
Has Results
  • Squamous NSCLC
  • Shanghai, China
    Shanghai Pulmonary Hospital
Mar 8, 2021

Non-Small-Cell Lung Carcinoma NSCLC Trial in Worldwide (MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel +

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma NSCLC
  • MEDI4736 (Durvalumab)
  • +7 more
  • Scottsdale, Arizona
  • +198 more
Jul 12, 2022

NSCLC Trial in Worldwide (Tepotinib, Gefitinib, Pemetrexed)

Completed
Has Results
  • Non-small Cell Lung Cancer
  • Beijing, China
  • +43 more
Oct 13, 2022

Non Small Cell Lung Cancer Trial in Beijing, Tianjin (Almonertinib, Almonertinib plus carboplatin and pemetrexed)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Beijing, China
  • +4 more
Aug 2, 2020

Advanced NSCLC Trial in Jinan (almonertinib)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • Jinan, Shandong, China
    Degan Lu
Sep 12, 2023

Non Small Cell Lung Cancer Trial in Beijing, Tianjin (Almonertinib, Almonertinib plus carboplatin and pemetrexed)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Beijing, Beijing, China
  • +5 more
Aug 4, 2020

NSCLC Trial in Worldwide (Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291)

Recruiting
  • Non-small Cell Lung Cancer
  • Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
  • Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
  • Silver Spring, Maryland
  • +43 more
Aug 8, 2022

NSCLC NSCLC Trial in Worldwide (Durvalumab, Placebo for Olaparib, Olaparib)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer NSCLC
  • Bonita Springs, Florida
  • +67 more
Nov 15, 2022

Advanced Malignant Solid Tumor, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 Trial in Los Angeles

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +8 more
  • Atezolizumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Feb 7, 2022

Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

Completed
  • Non-small Cell Lung Cancer
  • (no location specified)
May 8, 2023

NSCLC Trial in Worldwide (Lazertinib 240 mg/160 mg, Gefitinib 250 mg, Lazertinib-matching 240 mg/160 mg)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Lazertinib 240 mg/160 mg
  • +3 more
  • Woolloongabba, Queensland, Australia
  • +79 more
Nov 1, 2022

NSCLC Trial in Chongqing (Aumonertinib 165mg orally once daily and intrathecal chemo with pemetrexed)

Recruiting
  • Non-small Cell Lung Cancer
  • Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed
  • Chongqing, China
    chongqing University Three Gorges Hospital
Apr 11, 2023

NSCLC Stage III, EGFR Positive NSCLC, Non-squamous Non-small-cell Lung Cancer Trial in Korea, Republic of (Lazertinib)

Recruiting
  • Non-small Cell Lung Cancer Stage III
  • +2 more
  • Busan, Korea, Republic of
  • +12 more
Jan 17, 2023

Ovarian Cancer Trial in Milwaukee (Pembrolizumab, Carboplatin, Paclitaxel)

Active, not recruiting
  • Ovarian Cancer
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Apr 7, 2022